NATALIZUMAB EXTENDED INTERVAL DOSING (EID) IS ASSOCIATED WITH A SIGNIFICANT REDUCTION IN PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) RISK COMPARED WITH STANDARD INTERVAL DOSING (SID) IN THE TOUCH (R) PRESCRIBING PROGRAM

Ryerson Lana Zhovtis; Foley John; Chang Ih; Kister Ilya; Cutter Gary; Metzger Ryan; Goldberg Judith D.; Li Xiaochun; Riddle Evan; Smirnakis Karen; Yu Bei; Ren Zheng; Hotermans Christophe; Ho Pei-Ran; Campbell Nolan

首页> 外文期刊>Journal of Neurology, Neurosurgery and Psychiatry >NATALIZUMAB EXTENDED INTERVAL DOSING (EID) IS ASSOCIATED WITH A SIGNIFICANT REDUCTION IN PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) RISK COMPARED WITH STANDARD INTERVAL DOSING (SID) IN THE TOUCH (R) PRESCRIBING PROGRAM

【24h】

NATALIZUMAB EXTENDED INTERVAL DOSING (EID) IS ASSOCIATED WITH A SIGNIFICANT REDUCTION IN PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) RISK COMPARED WITH STANDARD INTERVAL DOSING (SID) IN THE TOUCH (R) PRESCRIBING PROGRAM

机译：与触摸（R）规定程序中的标准间隔给药（SID）相比，Natalizumab延长间隔给药（EID）与渐进式多焦白血病（PML）风险的显着降低有关

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of Neurology, Neurosurgery and Psychiatry》 |2018年第6期|共1页
作者
Ryerson Lana Zhovtis; Foley John; Chang Ih; Kister Ilya; Cutter Gary; Metzger Ryan; Goldberg Judith D.; Li Xiaochun; Riddle Evan; Smirnakis Karen; Yu Bei; Ren Zheng; Hotermans Christophe; Ho Pei-Ran; Campbell Nolan;
展开▼
作者单位

NYU Dept Neurol NYU Langone Hlth New York NY 10016 USA;

Rocky Mt MS Clin Salt Lake City UT USA;

Biogen Cambridge MA USA;

NYU Dept Neurol NYU Langone Hlth New York NY 10016 USA;

Univ Alabama Birmingham Sch Publ Hlth Birmingham AL 35294 USA;

Rocky Mt MS Clin Salt Lake City UT USA;

NYU Sch Med New York NY USA;

NYU Sch Med New York NY USA;

Biogen Cambridge MA USA;

Biogen Cambridge MA USA;

Biogen Cambridge MA USA;

Biogen Cambridge MA USA;

Biogen Cambridge MA USA;

Biogen Cambridge MA USA;

Biogen Cambridge MA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类神经病学;
关键词

相似文献

外文文献
专利

1. NATALIZUMAB EXTENDED INTERVAL DOSING (EID) IS ASSOCIATED WITH A SIGNIFICANT REDUCTION IN PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) RISK COMPARED WITH STANDARD INTERVAL DOSING (SID) IN THE TOUCH (R) PRESCRIBING PROGRAM [J] . Ryerson Lana Zhovtis, Foley John, Chang Ih, Journal of Neurology, Neurosurgery and Psychiatry . 2018,第6期

机译：与触摸（R）规定程序中的标准间隔给药（SID）相比，Natalizumab延长间隔给药（EID）与渐进式多焦白血病（PML）风险的显着降低有关
2. Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen [J] . Jose Vicente Hervas-Garcia, Silvia Presas-Rodriguez Neurodegenerative disease management . 2015,第5期

机译：与那他珠单抗延长给药方案相关的进行性多灶性白质脑病
3. Four cases of natalizumab-related PML: a less severe course in extended interval dosing? [J] . Scarpazza Cristina, De Rossi Nicola, Tabiadon Giulietta, Neurological sciences . 2019,第10期

机译：Natalizumab相关的PML四种情况：延长间隔给药时的严重课程
4. Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing [O] . Torge Rempe, Qin Wang, Qi Wu, 2020

机译：在那他珠单抗延长间隔给药中进行性新发多灶性白质脑病和颗粒细胞神经病伴新突变的VP1 C末端
5. Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML). [O] . Ruth Schneider, Barbara Bellenberg, Robert Hoepner, 2017

机译：1H-磁共振波谱学代谢曲线在natalizumab相关的多发性硬化患者的pmL后病变中，这些患者在进行性多灶性白质脑病（pmL）中存活。

NATALIZUMAB EXTENDED INTERVAL DOSING (EID) IS ASSOCIATED WITH A SIGNIFICANT REDUCTION IN PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) RISK COMPARED WITH STANDARD INTERVAL DOSING (SID) IN THE TOUCH (R) PRESCRIBING PROGRAM

著录项

相似文献

相关主题

期刊订阅